{"id":742229,"date":"2012-04-18T14:42:00","date_gmt":"2012-04-18T14:42:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-fosamax-alendronate-sodium-state-court-trial\/"},"modified":"2023-03-22T00:04:24","modified_gmt":"2023-03-22T04:04:24","slug":"merck-wins-another-fosamax-alendronate-sodium-state-court-trial","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-fosamax-alendronate-sodium-state-court-trial\/","title":{"rendered":"Merck Wins Another FOSAMAX\u00ae (alendronate sodium) State Court Trial"},"content":{"rendered":"<p class=\"bwalignc\">       New Jersey Jury Rejects Plaintiff\u2019s Claims     <\/p>\n<p>WHITEHOUSE STATION, N.J.&#8211;(BUSINESS WIRE)&#8211;Merck, known outside the United States and Canada as MSD, today said a        state court jury in New Jersey found in its favor in the <i>Sessner v.        Merck<\/i> case, rejecting the claims of a woman who blamed her        jaw-related problems on her FOSAMAX use.     <\/p>\n<p>       \u201cWe believe the evidence showed the company acted properly, and that        FOSAMAX did not cause the plaintiff\u2019s dental and jaw problems,\u201d said        Christy Jones of Butler, Snow, O\u2019Mara, Stevens &amp; Cannada PLLC, outside        counsel for Merck. \u201cUnfortunately, the plaintiff had medical conditions        that can result in the development of jaw and dental problems in people,        regardless of whether they were taking FOSAMAX. She had evidence of        significant infections that required invasive dental procedures and had        conditions that inhibit the body\u2019s ability to heal.\u201d     <\/p>\n<p>       With today&#8217;s verdict, Merck won the second state court case to go to        trial in the coordinated New Jersey FOSAMAX litigation. The plaintiff in        this case alleged she used FOSAMAX from 2002 to 2008 and that she        suffered various jaw problems and complications following the extraction        of four teeth in October 2007.     <\/p>\n<p>       At trial, Merck presented evidence that it acted responsibly in        researching and developing FOSAMAX and in monitoring the medicine since        it has been on the market. The company\u2019s clinical trials, conducted both        before and following approval, have involved more than 28,000 patients,        including more than 17,000 treated with FOSAMAX.     <\/p>\n<p>       \u201cWe agree with the jury\u2019s verdict. The company provided appropriate and        timely information about FOSAMAX to consumers and the medical,        scientific and regulatory communities,\u201d said Bruce N. Kuhlik, executive        vice president and general counsel of Merck. &#8220;FOSAMAX is a safe and        effective medicine when used in accordance with the label.\u201d     <\/p>\n<p>       Judge Carol E. Higbee of the Superior Court for Atlantic County, N.J.,        presided over the trial. Merck is represented by Christy Jones of        Butler, Snow, O\u2019Mara, Stevens &amp; Cannada PLLC in Ridgeland, Miss.; Eileen        Muskett of Fox Rothschild LLP in Atlantic City, N.J.; and Paul Strain of        Venable LLP in Baltimore, Md.     <\/p>\n<p>       <b>Status of FOSAMAX (alendronate sodium) Litigation<\/b>     <\/p>\n<p>       This is the sixth FOSAMAX case to go to trial. Merck has now won five of        the six trials. Four trials were conducted as part of the federal        multidistrict litigation proceedings before Judge John F. Keenan in the        U.S. District Court for the Southern District of New York: <i>Maley v.        Merck<\/i> resulted in a defense verdict for Merck in May 2010; <i>Boles        v. Merck<\/i> initially resulted in a mistrial in September 2009 after        the jury was unable to reach a unanimous verdict. A retrial of that case        in June 2010 resulted in a plaintiff verdict, which has since been        reduced by Judge Keenan and will be retried with respect to the amount        of damages in September 2012 and then appealed by Merck. <i>Graves v.        Merck<\/i> resulted in a defense verdict for Merck in November 2010. <i>Secrest        v. Merck<\/i> resulted in a defense verdict for Merck in October 2011.        The fifth case to go to trial, <i>Rosenberg v. Merck<\/i>, which was        tried in the Superior Court for Atlantic County, N.J., resulted in a        defense verdict for Merck in February 2011.     <\/p>\n<p>       As of&nbsp;Dec. 31, 2011, approximately&nbsp;2,345 cases, which include        approximately&nbsp;2,800 plaintiff groups, had been filed and were pending        against Merck in either federal or state court.     <\/p>\n<p>       <b>About FOSAMAX<\/b>     <\/p>\n<p>       FOSAMAX is indicated for the treatment and prevention of osteoporosis in        postmenopausal women. FOSAMAX should not be used&nbsp;in patients&nbsp;with        certain disorders of the esophagus that delay emptying, who are&nbsp;unable        to stand or sit upright for at least 30 minutes,&nbsp;who have low levels of        calcium in their blood,&nbsp;or in patients who are allergic to FOSAMAX. Some        patients may develop severe digestive reactions including irritation,        inflammation or ulceration of the esophagus. Dosing instructions should        be followed and patients who experience new or worsening heartburn,        difficulty or pain when swallowing or chest pain should stop taking the        drug and call their doctor right away. Patients who develop severe bone,        joint and\/or muscle pain at any time should contact their doctor.        Osteonecrosis of the jaw, generally associated with tooth extraction        and\/or local infection, with delayed healing, has been reported in        patients taking bisphosphonates, including FOSAMAX. Atypical femur        fractures have been reported in patients taking bisphosphonates.     <\/p>\n<p>       <b>About Merck<\/b>     <\/p>\n<p>       Today&#8217;s Merck is a global healthcare leader working to help the world be        well. Merck is known as MSD outside the United States and Canada.        Through our prescription medicines, vaccines, biologic therapies, and        consumer care and animal health products, we work with customers and        operate in more than 140 countries to deliver innovative health        solutions. We also demonstrate our commitment to increasing access to        healthcare through far-reaching policies, programs and partnerships. For        more information, visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50244248&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=ed9f49b70baaa0dc0736175670c0e2c8\" rel=\"noopener\">vip2-msd.com\/merckcom-migrated<\/a>        and connect with us on Twitter, Facebook and YouTube.     <\/p>\n<p>       <b>Forward-Looking Statement<\/b>     <\/p>\n<p>       This news release includes \u201cforward-looking statements\u201d within the        meaning of the safe harbor provisions of the United States Private        Securities Litigation Reform Act of 1995. Such statements may include,        but are not limited to, statements about the benefits of the merger        between Merck and Schering-Plough, including future financial and        operating results, the combined company\u2019s plans, objectives,        expectations and intentions and other statements that are not historical        facts. Such statements are based upon the current beliefs and        expectations of Merck\u2019s management and are subject to significant risks        and uncertainties. Actual results may differ from those set forth in the        forward-looking statements.     <\/p>\n<p>       The following factors, among others, could cause actual results to        differ from those set forth in the forward-looking statements: the        possibility that all of the expected synergies from the merger of Merck        and Schering-Plough will not be realized, or will not be realized within        the expected time period; the impact of pharmaceutical industry        regulation and health care legislation in the United States and        internationally; Merck\u2019s ability to accurately predict future market        conditions; dependence on the effectiveness of Merck\u2019s patents and other        protections for innovative products; and the exposure to litigation        and\/or regulatory actions.     <\/p>\n<p>       Merck undertakes no obligation to publicly update any forward-looking        statement, whether as a result of new information, future events or        otherwise. Additional factors that could cause results to differ        materially from those described in the forward-looking statements can be        found in Merck\u2019s 2011 Annual Report on Form 10-K and the company\u2019s other        filings with the Securities and Exchange Commission (SEC) available at        the SEC\u2019s Internet site (<a href=\"http:\/\/www.sec.gov\" title=\"www.sec.gov\">www.sec.gov<\/a>).     <\/p>\n<p>       <b>Prescribing Information and Medication Guide for FOSAMAX (alendronate        sodium) are available at:<\/b>     <\/p>\n<p>       <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Ff%2Ffosamax%2Ffosamax_pi.pdf&amp;esheet=50244248&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Ff%2FFOSAMAX%2FFOSAMAX_pi.pdf&amp;index=2&amp;md5=9704cfa8eb4e603bdf32eab3ad8a3786\" rel=\"noopener\"><b>vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/f\/FOSAMAX\/FOSAMAX_pi.pdf<\/b><\/a>     <\/p>\n<p>       <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Ff%2Ffosamax%2Ffosamax_mg.pdf&amp;esheet=50244248&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Ff%2FFOSAMAX%2FFOSAMAX_mg.pdf&amp;index=3&amp;md5=4dc796cd939fee347d6bb5549cf9bfe7\" rel=\"noopener\"><b>vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/f\/FOSAMAX\/FOSAMAX_mg.pdf<\/b><\/a>     <\/p>\n<p>       <b>FOSAMAX<\/b><sup><b>\u00ae<\/b><\/sup><b> is a registered trademark of Merck        Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., Whitehouse        Station, N.J., U.S.A.<\/b>     <\/p>\n<p class=\"bwalignc\">\n<p><p>       Merck<br \/>Media Contact: Ron Rogers, (908) 423-6449<br \/>Investor        Contact: Carol Ferguson, (908) 423-4465     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck, known outside the United States and Canada as MSD, today said a state court jury in New Jersey found in its favor in the Sessner v. Merck case, rejecting the claims of a woman who blamed her jaw-related problems on her FOSAMAX use. \u201cWe believe the evidence showed the company acted properly, and that FOSAMAX did not cause the plaintiff\u2019s dental and jaw problems,\u201d said Christy Jones of Butler, Snow, O\u2019Mara, Stevens &amp; Cannada PLLC, outside counsel for Merck. \u201cUnfortunately, the plaintiff had medical conditions that can result in the development of jaw and dental problems in people, regardless of whether they were taking FOSAMAX. She had evidence of significant infections that required invasive dental procedures and had conditions that inhibit the body\u2019s ability to heal.\u201d With today&#8217;s verdict, Merck won the second state court case to go to trial in the coordinated New Jersey FOSAMAX litigation. The plaintiff in this case alleged she used FOSAMAX from 2002 to 2008 and that she<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742229","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Wins Another FOSAMAX\u00ae (alendronate sodium) State Court Trial - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-fosamax-alendronate-sodium-state-court-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Wins Another FOSAMAX\u00ae (alendronate sodium) State Court Trial - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck, known outside the United States and Canada as MSD, today said a state court jury in New Jersey found in its favor in the Sessner v. Merck case, rejecting the claims of a woman who blamed her jaw-related problems on her FOSAMAX use. \u201cWe believe the evidence showed the company acted properly, and that FOSAMAX did not cause the plaintiff\u2019s dental and jaw problems,\u201d said Christy Jones of Butler, Snow, O\u2019Mara, Stevens &amp; Cannada PLLC, outside counsel for Merck. \u201cUnfortunately, the plaintiff had medical conditions that can result in the development of jaw and dental problems in people, regardless of whether they were taking FOSAMAX. She had evidence of significant infections that required invasive dental procedures and had conditions that inhibit the body\u2019s ability to heal.\u201d With today&#039;s verdict, Merck won the second state court case to go to trial in the coordinated New Jersey FOSAMAX litigation. The plaintiff in this case alleged she used FOSAMAX from 2002 to 2008 and that she\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-fosamax-alendronate-sodium-state-court-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-wins-another-fosamax-alendronate-sodium-state-court-trial\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-wins-another-fosamax-alendronate-sodium-state-court-trial\\\/\",\"name\":\"Merck Wins Another FOSAMAX\u00ae (alendronate sodium) State Court Trial - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2012-04-18T14:42:00+00:00\",\"dateModified\":\"2023-03-22T04:04:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-wins-another-fosamax-alendronate-sodium-state-court-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-wins-another-fosamax-alendronate-sodium-state-court-trial\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-wins-another-fosamax-alendronate-sodium-state-court-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Wins Another FOSAMAX\u00ae (alendronate sodium) State Court Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Wins Another FOSAMAX\u00ae (alendronate sodium) State Court Trial - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-fosamax-alendronate-sodium-state-court-trial\/","og_locale":"en_US","og_type":"article","og_title":"Merck Wins Another FOSAMAX\u00ae (alendronate sodium) State Court Trial - Merck.com","og_description":"Merck, known outside the United States and Canada as MSD, today said a state court jury in New Jersey found in its favor in the Sessner v. Merck case, rejecting the claims of a woman who blamed her jaw-related problems on her FOSAMAX use. \u201cWe believe the evidence showed the company acted properly, and that FOSAMAX did not cause the plaintiff\u2019s dental and jaw problems,\u201d said Christy Jones of Butler, Snow, O\u2019Mara, Stevens &amp; Cannada PLLC, outside counsel for Merck. \u201cUnfortunately, the plaintiff had medical conditions that can result in the development of jaw and dental problems in people, regardless of whether they were taking FOSAMAX. She had evidence of significant infections that required invasive dental procedures and had conditions that inhibit the body\u2019s ability to heal.\u201d With today's verdict, Merck won the second state court case to go to trial in the coordinated New Jersey FOSAMAX litigation. The plaintiff in this case alleged she used FOSAMAX from 2002 to 2008 and that she","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-fosamax-alendronate-sodium-state-court-trial\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:24+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-fosamax-alendronate-sodium-state-court-trial\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-fosamax-alendronate-sodium-state-court-trial\/","name":"Merck Wins Another FOSAMAX\u00ae (alendronate sodium) State Court Trial - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2012-04-18T14:42:00+00:00","dateModified":"2023-03-22T04:04:24+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-fosamax-alendronate-sodium-state-court-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-fosamax-alendronate-sodium-state-court-trial\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-wins-another-fosamax-alendronate-sodium-state-court-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Wins Another FOSAMAX\u00ae (alendronate sodium) State Court Trial"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"391d2ea1-0e04-463b-8289-027a3cabbe03","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Wins-Another-FOSAMAX-alendronate-sodium-State-Court-Trial-2012.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742229","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742229\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742229"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}